Maternal HIV Testing and Identification of Perinatal HIV Exposure

(Last updated December 30, 2021; last reviewed December 30, 2021)

Panel’s Recommendations

- HIV testing is recommended as a standard of care for all sexually active people and should be a routine component of preconception care (AII).

- All pregnant people should be tested as early as possible during each pregnancy (see Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations and Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens from the Centers for Disease Control and Prevention [CDC]) (AII).

- Partners of all pregnant people should be referred for HIV testing when their status is unknown (AIII).

- Repeat HIV testing in the third trimester is recommended for pregnant people with negative initial HIV tests who are at increased risk of acquiring HIV, including those receiving care in facilities that have an HIV incidence of ≥1 case per 1,000 pregnant women per year, those who reside in jurisdictions with elevated HIV incidence (see Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings from CDC), or those who reside in states or territories that require third-trimester testing (AII).

- Repeat HIV testing is recommended for pregnant people with a sexually transmitted infection (STI) or with signs and symptoms of acute HIV infection, or ongoing exposure to HIV, as well as referral for initiation of pre-exposure prophylaxis if HIV testing is negative (AIII). See Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods for more information.

- Expedited HIV testing should be performed during labor or delivery for people with undocumented HIV status and for those who tested negative early in pregnancy but are at increased risk of HIV infection and were not retested in the third trimester (AII). Testing should be available 24 hours a day, and results should be available within 1 hour. If results are positive, intrapartum antiretroviral (ARV) prophylaxis should be initiated immediately (AI).

- Pregnant people who were not tested for HIV before or during labor should undergo expedited HIV antibody testing during the immediate postpartum period (or their newborns should undergo expedited HIV antibody testing) (AII).

- When a pregnant person has a positive HIV test result during labor and delivery or postpartum, or when a newborn’s expedited antibody test is positive, an appropriate infant ARV drug regimen should be initiated immediately, and the infant should not be breastfed while awaiting the results of supplemental HIV testing (AII). See Antiretroviral Management of Newborns with Perinatal HIV Exposure or Perinatal HIV for guidance.

- Results of maternal HIV testing should be documented in the newborn’s medical record and communicated to the newborn’s primary care provider (AIII).

- HIV testing is recommended for infants and children in foster care and adoptees for whom maternal HIV status is unknown to identify perinatal HIV exposure and possible HIV infection (AII) (see Diagnosis of HIV Infections in Infants and Children).
HIV Testing in Pregnancy

HIV infection should be identified before pregnancy (see Prepregnancy Counseling and Care for Persons of Childbearing Age with HIV) or as early as possible in pregnancy. In the United States, approximately 20% to 34% of infants with perinatal HIV exposure were born to people whose HIV diagnosis was not known before pregnancy. Early diagnosis provides the best opportunity to improve maternal health and pregnancy outcomes to prevent infant acquisition of HIV, to identify HIV infection, and to start therapy as soon as possible in infants who acquire HIV. Universal voluntary HIV testing is recommended as the standard of care for all pregnant people in the United States by the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV and the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission (the Panels), the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the U.S. Preventive Services Task Force.

All HIV testing should be performed in a manner that is consistent with state and local regulations. CDC recommends the “opt-out” approach, which is allowed in many jurisdictions and involves notifying a pregnant person that HIV testing will be performed as part of routine care unless they choose not to be tested. The “opt-in” approach involves obtaining specific consent before testing, and this approach has been associated with lower testing rates. Despite the guidelines for universal HIV screening of pregnant people, recent studies indicate that fewer than 80% of women report having been tested for HIV during pregnancy. The mandatory newborn HIV testing approach, which has been adopted by several states, involves testing newborns with or without maternal consent. In some areas, this applies to all newborns; in others, it applies only to the infants of mothers who have declined prenatal or intrapartum testing.

Partners of pregnant people should be referred for HIV testing when their status is unknown, consistent with the 2006 CDC recommendations for HIV testing of all individuals in the United States. Testing will facilitate linkage to care if a partner is diagnosed with HIV infection. Because women are more susceptible to HIV acquisition during pregnancy and the postpartum period, clinicians also can initiate a discussion about preventive interventions, including pre-exposure prophylaxis (PrEP), for a pregnant person without HIV who is at risk for acquiring HIV. See Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods for more information.

Clinicians should assess a pregnant person’s risk of acute HIV infection, particularly late in pregnancy, because people may receive a negative result for expedited or rapid HIV testing when they are in the window period (the window period lasts up to 15 days post-infection when using the combined antigen/antibody immunoassay and up to 28 days when using other assays). However,
during this period, the person with acute HIV will be viremic,\textsuperscript{12} with a high risk of perinatal transmission to the newborn. The HIV RNA assay can detect the presence of HIV as early as 10 days post-infection, so this test should be used when acute HIV infection is suspected. See \textit{Acute HIV Infection} for more information.

Providers should be aware that gaps in maternal HIV testing do occur and can contribute to missed opportunities for preventing perinatal HIV transmission.\textsuperscript{13-16} Maternal HIV testing should be performed as early as possible during pregnancy, wherever a person seeks care (including emergency departments and prenatal clinics), to avoid missed opportunities to identify pregnant people with HIV. Repeat HIV testing should be performed in the third trimester for people who are at increased risk of acquiring HIV or who are living in areas of high HIV incidence, at the time of a diagnosis of a sexually transmitted infection (STI), or when they show symptoms and signs of possible acute HIV infection. Pregnant people with unknown or undocumented HIV status who present to care in labor should be tested during delivery or as soon as possible after delivery.\textsuperscript{13-16}

Determining antenatal maternal HIV status enables—

- People with HIV to receive appropriate antiretroviral therapy (ART) and prophylaxis against opportunistic infections;
- Initiation of treatment in the identified people to maintain and improve their health and to decrease risk of HIV transmission to their fetus or infant and their partners;\textsuperscript{3,17,18}
- Referral of partners for testing, which allows them to initiate either treatment if the results are positive or preventive interventions, including PrEP, if the results are negative if warranted (see \textit{Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods});
- Provision of ART during pregnancy and labor and provision of an appropriate antiretroviral (ARV) drug regimen to the newborn to reduce the risk of perinatal transmission;
- Counseling of pregnant people with HIV about recommended modes of delivery based on individualized risks of perinatal transmission of HIV;\textsuperscript{19-21}
- Counseling of pregnant people with HIV about the risks of HIV transmission through breast milk (in the United States, breastfeeding is not recommended for women with HIV [see \textit{Counseling and Managing Individuals with HIV in the United States Who Desire to Breastfeed}]);\textsuperscript{22} and
- Early diagnostic evaluation of infants exposed to HIV (see \textit{Diagnosis of HIV Infection in Infants and Children}), as well as testing of other children, to permit prompt initiation of ART and any indicated prophylaxis measures.\textsuperscript{2,23-25}

New technology has made it possible to detect HIV earlier and has reduced the performance time for laboratory-based assays, which now can be completed in <1 hour. Accordingly, the Panels now base their recommendations for HIV testing on CDC’s 2014 \textit{Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations}.\textsuperscript{26} The guidelines recommend that clinicians initiate HIV testing with an immunoassay that is capable of detecting HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen (referred to as an antigen/antibody combination immunoassay). Individuals with a reactive antigen/antibody combination immunoassay should be tested further with an HIV-1/HIV-2 antibody differentiation assay (referred to as supplemental testing). Individuals with a reactive antigen/antibody combination immunoassay and a nonreactive differentiation test should be tested with a Food and Drug Administration–approved plasma HIV RNA assay to establish a diagnosis of
Discordant HIV testing results can be seen, requiring careful evaluation and often repeat tests. Early in HIV infection, before HIV seroconversion, the antigen-antibody screen will be negative and the HIV RNA assay will be positive. This is seen in acute infection because the HIV RNA assay is positive before the antigen/antibody screen. The test combination of a positive antigen-antibody screen, negative antibody differentiation assay, and positive HIV RNA assay also can be seen early in HIV infection because the IgG-based antibody differentiation assay is positive later in infection than the antigen capture or the IgM result in the antigen-antibody screen.

Clinicians should be aware that as more individuals undergo repeat HIV testing, the number of false-positive screens will increase. The combination of a positive antigen-antibody screen with a negative antibody differentiation assay and a negative HIV RNA assay is seen in people without HIV who have a false-positive antigen-antibody screen.

These examples should make it clear that for any positive HIV 1/2 antigen-antibody screen, an HIV RNA assay should be done because the HIV RNA assay is needed to resolve questions raised by discordant results on the antigen-antibody screen and the antibody differentiation assay.

The antigen/antibody combination immunoassay is the test of choice and can be done quickly (referred to as an expedited test), but it requires trained laboratory staff and, therefore, may not be available in some hospitals 24 hours a day. When this test is unavailable, initial testing should be performed by the most sensitive expedited or rapid test available. Every delivery unit needs to have access to an HIV test that can be done rapidly (i.e., in <1 hour) 24 hours a day. If the test result is positive, the test to confirm HIV infection should be performed as soon as possible (as with all initial assays with positive results). Older antibody tests have lower sensitivity in the context of recent acquisition of HIV than antigen/antibody combination immunoassays. Therefore, testing that follows the 2014 CDC algorithm should be considered if HIV risk cannot be ruled out. Results of maternal HIV testing should be documented in the newborn’s medical record and communicated to the newborn’s primary care provider.

**Repeat HIV Testing in the Third Trimester**

Repeat HIV testing during the third trimester, before 36 weeks gestation, is recommended (see *Acute HIV Infection*) for pregnant people with negative results on their initial HIV antibody tests who—

- Are at high risk of acquiring HIV (e.g., those who inject drugs or have sex with people who inject drugs, those who exchange sex for money or drugs, those who are sex partners of individuals with HIV, those who have had a new sex partner or more than one sex partner during the current pregnancy, or those who have a suspected or diagnosed STI during pregnancy); or
- Are receiving health care in facilities where prenatal screening identifies one or more pregnant women with HIV per 1,000 women screened, or reside in a jurisdiction that has a high incidence

(acute HIV infection (see CDC’s [Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens](https://www.cdc.gov/hiv/testing/lab TESTING ALGORITHM.html)).)
Reside in states or territories with statutes or regulations that require third-trimester testing (Arizona, Connecticut, Delaware, Florida, Georgia, Illinois, Louisiana, Maryland, Nevada, New Jersey, North Carolina, Tennessee, Texas, Virginia, West Virginia); or

• Have signs or symptoms of acute HIV (e.g., fever, lymphadenopathy, skin rash, myalgia, headaches, oral ulcers, leukopenia, thrombocytopenia, elevated transaminase levels).

In addition, third-trimester testing should be offered to pregnant people who perceive themselves as being at increased risk for HIV infection (regardless of whether or not they fit any of the above criteria). Pregnant people who decline testing earlier in pregnancy should be offered testing again during the third trimester. An antigen/antibody combination immunoassay should be used because these tests have a higher sensitivity in the setting of acute HIV infection than older antibody tests. When acute HIV infection is suspected during pregnancy, during the intrapartum period, or while breastfeeding, a plasma HIV RNA test result should be performed in conjunction with an antigen/antibody combination immunoassay. See Acute and Recent (Early) HIV Infection in the Adult and Adolescent Antiretroviral Guidelines for more information.

Repeat HIV testing at other times during pregnancy also should be considered when clinically indicated. For example, repeat testing should be performed when a pregnant person presents with symptoms that are suggestive of an STI, a confirmed STI diagnosis, or symptoms or signs that are consistent with acute HIV infection.

HIV Testing During Labor in People with Unknown HIV Status

People in labor whose HIV status is undocumented and those who tested negative early in pregnancy but are at increased risk of HIV infection and were not retested in the third trimester should undergo expedited HIV testing to identify HIV infection in the mothers and HIV exposure in their infants. HIV testing during labor has been found to be feasible, accurate, timely, and useful both in ensuring prompt initiation of intrapartum maternal ARV for fetal/infant prophylaxis (see Intrapartum Care for...
People with HIV) and in developing an appropriate ARV regimen for infants who are at high risk of perinatal HIV transmission (see Table 11). A positive expedited HIV test result must be followed by a supplemental test. Immediate initiation of maternal intravenous intrapartum zidovudine is recommended to prevent perinatal transmission of HIV pending the supplemental result (see Intrapartum Care for People with HIV). Pending results of supplemental maternal testing, infants should receive an ARV regimen that is appropriate for infants who are at high risk of perinatal HIV transmission as soon as possible (see Antiretroviral Management of Newborns with Perinatal HIV Exposure or Perinatal HIV or contact the National Clinician Consultation Center Perinatal HIV Hotline). No further testing is required for specimens that are nonreactive (negative) on the initial immunoassay, unless acute HIV infection is suspected (see Acute HIV Infection). HIV Testing During the Postpartum Period

People who have not been tested for HIV before or during labor should be offered expedited testing during the immediate postpartum period. Maternal testing should be done using the antigen/antibody combination immunoassay to screen for established and acute HIV; results should be obtained in <1 hour. If acute HIV infection is a possibility, then a plasma HIV RNA test should be sent, as well. When mothers are unavailable for testing, their newborns should undergo expedited HIV testing. Postnatal ARV drugs need to be initiated as soon as possible—ideally ≤6 hours after birth—to be effective in preventing perinatal transmission. When an initial HIV test is positive in mothers or infants, it is strongly recommended that clinicians initiate an ARV regimen that is appropriate for infants who are at high risk of perinatal HIV transmission and counsel the mothers against breastfeeding pending the results of supplemental testing, which should include a plasma HIV RNA test. Breast milk can be expressed while HIV diagnostic testing is being completed, but it should not be given to the infant until testing confirms that the mother is HIV negative (see Antiretroviral Management of Newborns with Perinatal HIV Exposure or Perinatal HIV). If supplemental test results are negative and acute HIV is excluded, infant ARV drugs can be discontinued. In the absence of ongoing maternal HIV exposure, breastfeeding can be initiated. Consultation with a pediatric HIV specialist is strongly recommended if questions remain about the potential for acute maternal infection or ongoing maternal HIV exposure.

Infant HIV Testing When Maternal HIV Test Results Are Unavailable

When maternal HIV test results are unavailable (e.g., the mother has declined testing during pregnancy or for infants and children who are in foster care) or their accuracy cannot be evaluated (e.g., for infants and children who were adopted from countries where results are not reported in English), HIV testing of these infants or children is indicated to identify HIV exposure and possible infection. The choice of test will vary based on the age of the child (see Diagnosis of HIV Infection).
Mechanisms should be developed to facilitate prompt HIV screening for infants who have been abandoned and who are in the custody of the state.

**Acute Maternal HIV Infection During Pregnancy or Breastfeeding**

Women are more susceptible to HIV infection during pregnancy and the early postpartum period. Risk of HIV exposure should be assessed in all people who are considering becoming pregnant, as well as in all pregnant and postpartum people who previously tested negative for HIV, including those who are breastfeeding. People with risk factors for HIV acquisition before, during, and after pregnancy should receive prevention counseling and appropriate interventions, including PrEP if indicated. (See [Prepregnancy Counseling and Care for Persons of Childbearing Age with HIV](https://www.cdc.gov/hiv/risk/prep.html) and [Pre-Exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods](https://www.cdc.gov/hiv/risk/prep.html) for more information. People who have acute HIV during pregnancy or lactation have an increased risk of perinatal transmission and secondary sexual transmission of HIV (see [Acute HIV Infection](https://www.cdc.gov/hiv/risk/acute.html)).

The antigen/antibody combination immunoassay will detect acute HIV infection earlier than other immunoassays—within approximately 15 days of acquisition. When acute HIV infection is suspected, a plasma HIV RNA test should be sent as well because virologic tests can detect the presence of HIV approximately 5 days earlier than the antigen/antibody combination immunoassay.

People with possible acute HIV infection who are breastfeeding should cease breastfeeding immediately until HIV infection is confirmed or excluded. Breast milk can be expressed while HIV diagnostic testing is completed. Breastfeeding can resume if HIV infection is excluded and there is no ongoing risk. Care of pregnant or breastfeeding people with acute or early HIV, and their infants, should follow the recommendations in the Perinatal Guidelines (see [Acute HIV Infection](https://www.cdc.gov/hiv/risk/acute.html) and [Guidance for Counseling and Managing Individuals with HIV in the United States Who Desire to Breastfeed](https://www.cdc.gov/hiv/guidelines/)).

**Other Issues**

Clinicians should be aware of public health surveillance systems and regulations that may exist in their jurisdictions for reporting infants who have been exposed to HIV; this is in addition to mandatory reporting of people with HIV, including infants. Reporting infants who have been exposed to HIV allows the appropriate public health functions to be accomplished.
References


11. Thomson KA, Hughes J, Baeten JM, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis


43. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and